SICKLE CELL DISEASE PREVENTION AND TREATMENT.

SEC. 3. SICKLE CELL DISEASE PREVENTION AND TREATMENT. (a) Reauthorization.—Section 712(c) of the American Jobs Creation Act of 2004 (Public Law 108-357; 42 U.S.C. 300b-1 note) is amended— (1) by striking “Sickle Cell Disease” each place it appears and inserting “sickle cell disease”; (2) in paragraph (1)(A), by striking “shall conduct a demonstration program by making grants to up to 40 eligible entities for each fiscal year in which the program is conducted under this section for the purpose of developing and establishing systemic mechanisms to improve the prevention and treatment of Sickle Cell Disease” and inserting “shall continue efforts, including by awarding grants, to develop or establish mechanisms to improve the treatment of sickle cell disease, and to improve the prevention and treatment of complications of sickle cell disease, in populations with a high proportion of individuals with sickle cell disease”; (3) in paragraph (1)(B)— (A) by striking clause (ii) (relating to priority); and (B) by striking “Grant award requirements” and all that follows through “The Administrator shall” and inserting “Geographic diversity.—The Administrator shall”; (4) in paragraph (2), by adding the following new subparagraph at the end: “(E) To provide or coordinate services for adolescents with sickle cell disease making the transition to adult health care.” ; and (5) in paragraph (6), by striking “$10,000,000 for each of fiscal years 2005 through 2009” and inserting “$4,455,000 for each of fiscal years 2019 through 2023”. (b) Technical Changes.—Subsection (c) of section 712 of the American Jobs Creation Act of 2004 (Public Law 108-357; 42 U.S.C. 300b-1 note), as amended by subsection (a), is— (1) transferred to the Public Health Service Act (42 U.S.C. 201 et seq.); (2) redesignated as subsection (b); and (3) inserted at the end of section 1106 of such Act, as added by section 2 of this Act.